Operating the prescription pharmaceuticals business and consumer healthcare business as the two pillars
First written in FY2016. 20 of 23 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026Prioritizing renewed growth in both domestic businessesAnnual report
「During the period of the 12th Medium-Term Management Plan, generic competition is expected as the patent for DIFICLIR, which drove performance under the previous medium-term plan, reaches expiration. To prepare for this situation, we identified three key priorities: “further expansion of global operations,” “returning both domestic businesses to a growth trajectory,” and “expanding the development pipeline,”」
While maintaining the positioning of the prescription pharmaceuticals business and consumer healthcare business as the two pillars and core businesses, the 12th Medium-Term Management Plan explicitly identified returning both domestic businesses to a growth trajectory as a key priority. - FY2026-H1RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The prescription pharmaceuticals business and consumer healthcare business continue to be classified as the two major businesses, with the performance of each explained separately. - FY2023RestatedAnnual report
「The Group's distinguishing feature is balanced management based on its prescription pharmaceuticals business and consumer healthcare business. Sustainable growth is being achieved as each of the two core businesses contributes to earnings by capitalizing on its respective strengths.」
Balanced management based on the prescription pharmaceuticals business and consumer healthcare business as the two core businesses continues. - FY2023-Q2RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The prescription pharmaceuticals business and consumer healthcare business continue to be classified as the two major businesses, with the performance of each explained separately. - FY2023-Q1RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The prescription pharmaceuticals business and consumer healthcare business continue to be classified as the two major businesses, with the performance of each explained separately. - FY2022-Q3RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The prescription pharmaceuticals business and consumer healthcare business continue to be classified as the two major businesses, with the performance of each explained separately. - FY2022-Q2RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The prescription pharmaceuticals business and consumer healthcare business continue to be classified as the two major businesses, with the performance of each explained separately. - FY2022-Q1RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The prescription pharmaceuticals business and consumer healthcare business continue to be classified as the two major businesses, with the performance of each explained separately. - FY2020RestatedAnnual report
「The Group's distinguishing feature is balanced management based on its prescription pharmaceuticals business and consumer healthcare business. Sustainable growth is being achieved as each of the two core businesses contributes to earnings by capitalizing on its respective strengths.」
The prescription pharmaceuticals business and consumer healthcare business continue to be positioned as the two core businesses. - FY2020-Q3RestatedAnnual report
「With “Building health, building happiness” as our motto, we operate the prescription pharmaceuticals business and consumer healthcare business, centered on OTC pharmaceuticals, positioning them as the two pillars of our operations.」
The positioning of the prescription pharmaceuticals business and consumer healthcare business as the two pillars was reaffirmed in the explanation of the purpose of acquiring 日水製薬医薬品販売. - FY2020-Q2RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The prescription pharmaceuticals business and consumer healthcare business continue to be classified as the two major businesses, with the performance of each explained separately. - FY2020-Q1RestatedAnnual report
「The operating results by segment are as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The prescription pharmaceuticals business and consumer healthcare business continue to be classified as the two major businesses, with the performance of each explained separately. - FY2019RestatedAnnual report
「The Group's distinguishing feature is balanced management based on its prescription pharmaceuticals business and consumer healthcare business. Sustainable growth is being achieved as each of the two core businesses contributes to earnings by capitalizing on its respective strengths.」
The prescription pharmaceuticals business and consumer healthcare business continue to be positioned as the two core businesses. - FY2019-Q3RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The prescription pharmaceuticals business and consumer healthcare business continue to be classified as the two major businesses, with the performance of each explained separately. - FY2019-Q2RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The prescription pharmaceuticals business and consumer healthcare business continue to be classified as the two major businesses, with the performance of each explained separately. - FY2019-Q1RestatedAnnual report
「The operating results by segment are as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The prescription pharmaceuticals business and consumer healthcare business continue to be classified as the two major businesses, with the performance of each explained separately. - FY2018ReframedAnnual report
「The Group's distinguishing feature is balanced management based on its prescription pharmaceuticals business and consumer healthcare business. Sustainable growth is being achieved as each of the two core businesses contributes to earnings by capitalizing on its respective strengths.」
The strategic positioning is explained as balanced management based on two core businesses, rather than using the former expression of the two businesses as the two pillars. - FY2018-Q2RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The prescription pharmaceuticals business and consumer healthcare business continue to be classified as the two major businesses, with the performance of each explained separately. - FY2017RestatedAnnual report
「We have proactively invested management resources to drive growth in the prescription pharmaceuticals business and consumer healthcare business, which we have traditionally regarded as the two pillars of our operations.」
The two businesses continue to be positioned as the two pillars, and investment of management resources in both businesses continues. - FY2017-Q3RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The prescription pharmaceuticals business and consumer healthcare business continue to be classified as the two major businesses, with the performance of each explained separately. - FY2017-Q2RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The prescription pharmaceuticals business and consumer healthcare business continue to be operated as the two major businesses, with the performance of each explained separately. - FY2017-Q1RestatedAnnual report
「The performance of each segment is as follows: ① Prescription pharmaceuticals business ② Consumer healthcare business」
The prescription pharmaceuticals business and consumer healthcare business continue to be operated and disclosed as separate major segments. - FY2016First statedAnnual report
「We have strongly promoted the prescription pharmaceuticals business and consumer healthcare business, which we have traditionally regarded as the two pillars of our operations.」
The two businesses are positioned for parallel development as core businesses.